Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Blood (2024) 144 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2024-199055

Published: 2024

Journal Articles

Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Zi Yun Ng, Laurane Cottin, Damien Luque Paz, Corentin Orvain, Kamel Laribi, Jean-Christophe Ianotto, Eric Lippert, Alesia Khan, Daniel Lock, Valerie Ugo, Claire Harrison, Jennifer O'Sullivan

Blood (2024) 144 (Supplement 1): 485.

https://doi.org/10.1182/blood-2024-201326

Published: 2024

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Blood (2022) 140 (Supplement 1): 6847–6849.

https://doi.org/10.1182/blood-2022-156632

Published: 2022

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Peter AW te Boekhorst, MD PhD, Alexandre Theocharides, MD, Heinz Gisslinger, MD, Timothy Devos, MD, Eric Lippert, MD PhD, Damianos Sotiropoulos, MD, Miklos Egyed, MD PhD, Valerio De Stefano, MD, Vincenzo Accurso, MD, Alessandra Iurlo, MD PhD, Anders E.A. Dahm, MD PhD, Regina Garcia-Delgado, MD, Nathan Cantoni, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erik Houtsma, MSc, Amir Iqbal, PhD, Paola Di Matteo, MD PhD, Alberto Alvarez-Larrán, MD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134210

Published: 2020

Journal Articles

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Vaidie Julien, MD, Delphine Rea, MD, Sylvain Thepot, MD, Le Pluart Bruno, MD, Nathalie Gachard, PhD, Stéphanie Struski, MD, Lydia Roy, MD, Cecile Bally, MD, Jo Caers, MD PhD, Franck E Nicolini, MD PhD, Bruno Cassinat, PharmD, PhD, Eric Lippert, MD PhD, Laurence Legros, MD PhD, Raphael Itzykson, MD PhD

Blood (2019) 134 (Supplement_1): 2954.

https://doi.org/10.1182/blood-2019-127254

Published: 2019

Journal Articles

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Blood (2019) 134 (Supplement_1): 1537.

https://doi.org/10.1182/blood-2019-127560

Published: 2019

Journal Articles

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Frederic Picou, PhD, Jean-Claude Chomel, PharmD PhD, Marie Christine Bene, PharmD, Marc G. Berger, MD PhD, Thierry Fest, Valerie Ugo, MD PhD, Eric Lippert, MD PhD, Marion Socco-Luca, Martine Delain, MD, Marie-Helene Estienne, PharmD, Olivier Herault, MD PhD

Blood (2018) 132 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2018-99-118297

Published: 2018

Journal Articles

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Blood (2017) 130 (Supplement 1): 323.

https://doi.org/10.1182/blood.V130.Suppl_1.323.323

Published: 2017

Journal Articles

Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Cecile Bally, Jacqueline Lehmann-Che, Bruno Cassinat, PharmD, PhD, Lionel Ades, MD PhD, Eric Letouze, Pierre Hirsch, Marie-Joelle Mozziconacci, Sophie Raynaud, MD, Eric Delabesse, PharmD, PhD, Madalina Uzunov, MD, Mathilde Hunault, MD PhD, Eric Lippert, PhD, Hélène Lapillonne, MD PhD, Christophe Ferrand, PhD, Carine Gervais, MD, Nathalie Gachard, PhD, Agnès Guerci, MD PhD, Pierre Fenaux, MD PhD, Hugues de The, MD PhD

Blood (2016) 128 (22): 2892.

https://doi.org/10.1182/blood.V128.22.2892.2892

Published: 2016

Journal Articles

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Blood (2016) 128 (22): 3128.

https://doi.org/10.1182/blood.V128.22.3128.3128

Published: 2016

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Consequences of the Presence of the JAK2V617F Mutation in Endothelial Cells: Towards a Better Understanding of the Increased Angiogenesis in Myeloproliferative Neoplasms

Badr Kilani, Juliana Vieira Dias, PhD, Virginie Gourdou-Latyszenok, Eric Lippert, PhD, Raj Sewduth, Cécile Duplaa, PhD, Jean-Luc Villeval, PhD, Thierry Couffinhal, MD PhD, Chloe James, MD PhD

Blood (2014) 124 (21): 102.

https://doi.org/10.1182/blood.V124.21.102.102

Published: 2014

Journal Articles

JAK2 Exon 12 Mutant Allele Burden Study (JETMABS): A European Multicenter Study

Lasse Kjaer, Ph.D., Eric Lippert, Francois Girodon, MD, PhD, Susanne Schnittger, PhD, Serge Carillo, Caroline Riley, MD, Beatriz Bellosillo, Maj K. Westman, Ole Weis Bjerrum, MD, Marzena Wojtaszewska, Thomas Kristensen, MSc, PhD, Melanie Percy, PhD, Mary Frances McMullin, MD, MRCPath, Maruska Marusic, Caroline Rosmond, Lars Palmqvist, MD, PhD, Sylvie Hermouet, MD, Ph.D., Hans Carl Hasselbalch, MD, DMSc

Blood (2013) 122 (21): 4075.

https://doi.org/10.1182/blood.V122.21.4075.4075

Published: 2013

Journal Articles

High-Resolution Melting (HRM) Curve Analysis Is a Reliable and Relevant Tool In JAK2 V617F-Negative Myeloproliferative Neoplasms

Francois Girodon, MD, PhD, Eric Lippert, Sylvie Hermouet, MD, Ph.D., Serge Carillo, PhD

Blood (2013) 122 (21): 4077.

https://doi.org/10.1182/blood.V122.21.4077.4077

Published: 2013

Journal Articles

NOTCH1 Mutations Are Associated With The 14q Deletion In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Blood (2013) 122 (21): 2561.

https://doi.org/10.1182/blood.V122.21.2561.2561

Published: 2013

Journal Articles

Identification Of MGMT Polymorphisms As Genetic Markers Of Individual Susceptibility To Therapy-Related Myeloid Neoplasms

Julie Dubois, Gabriel Etienne, Audrey Laroche-Clary, Axelle Lascaux, MD, Audrey Bidet, Eric Lippert, Sofiane Aitouferoukh, Veronique Saada, Jean-Baptiste Micol, Krimo Bouabdallah, MD, Jacques Robert

Blood (2013) 122 (21): 1545.

https://doi.org/10.1182/blood.V122.21.1545.1545

Published: 2013

Journal Articles

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Gabriel Etienne, MD, PHD, Stephanie Dulucq, MD, Axelle Lascaux, MD, Anna Schmitt, MD, Audrey Bidet, Marie-Pierre Fort, Eric Lippert, Caroline Bureau, Didier Adiko, MD, Sandrine Hayette, Josy Reiffers, MD, Franck E. Nicolini, MD PhD, Francois-Xavier Mahon, MD, PhD

Blood (2013) 122 (21): 4029.

https://doi.org/10.1182/blood.V122.21.4029.4029

Published: 2013

Journal Articles

Analysis of SF3B1 in a Large Cohort of Refractory Anemia with Ring Sideroblasts with/without Marked Thrombocytosis (RARS-T/RARS) in an European Multicentre Study Reveals a High Incidence (86.3%) of Mutations and an Independent Favorable Association with Outcome

Susanne Schnittger, PhD, Ulrich Germing, Julien Broseus, Vera Grossmann, MSc, Tamara Alpermann, Lourdes Florensa Brichs, MD, Eric Lippert, PhD, Francois Liferman, MD, Sabine Jeromin, PhD, Torsten Haferlach, MD, Francois Girodon, MD, PhD

Blood (2012) 120 (21): 3798.

https://doi.org/10.1182/blood.V120.21.3798.3798

Published: 2012

NARROW

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Consequences of the Presence of the JAK2V617F Mutation in Endothelial Cells: Towards a Better Understanding of the Increased Angiogenesis in Myeloproliferative Neoplasms

JAK2 Exon 12 Mutant Allele Burden Study (JETMABS): A European Multicenter Study

High-Resolution Melting (HRM) Curve Analysis Is a Reliable and Relevant Tool In JAK2 V617F-Negative Myeloproliferative Neoplasms

NOTCH1 Mutations Are Associated With The 14q Deletion In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Identification Of MGMT Polymorphisms As Genetic Markers Of Individual Susceptibility To Therapy-Related Myeloid Neoplasms

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Analysis of SF3B1 in a Large Cohort of Refractory Anemia with Ring Sideroblasts with/without Marked Thrombocytosis (RARS-T/RARS) in an European Multicentre Study Reveals a High Incidence (86.3%) of Mutations and an Independent Favorable Association with Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only